Comparison of the efficacy of replication defective adenovirus and Nyvac poxvirus as vaccine vectors in mice
Comparison of the efficacy of replication defective adenovirus and Nyvac poxvirus as vaccine vectors in mice
复制标题
DOI：
10.1016/0264-410x(95)00226-q
复制
发表时间：
1996-08-01
期刊：
影响因子：
5.5
通讯作者：
Eloit, M
中科院分区：
文献类型：
--
作者：
Gonin, P;Oualikene, W;Eloit, M
腺病毒和痘病毒重组载体越来越多地被用作实验活疫苗。为了比较这些载体在引起血清学反应和抵御攻击方面的效果，将携带相同基因（伪狂犬病毒gD）的两种重组物作为实验疫苗用于小鼠（一种对伪狂犬感染的允许物种）。试验了两种途径：肌内注射（i.m）和鼻内注射（i.n），以尝试刺激全身和粘膜免疫反应。根据测试的疫苗，从10（2.9）到10(8.9)TCID50不等的几种剂量。腺病毒载体（Ad-gD）和Nyvac载体（vP900）的log10 （PD50）分别为7.1 +/- 0.2和7.6 +/- 0.2。对于inn路由，Ad-gD的log10 （PD50）为7.1 +/- 0.2，高于vP900的7.9。虽然证明腺病毒载体比痘病毒载体更有效地引发抗体反应，但在比较攻击后动物的存活时间时，只观察到轻微的差异。腺病毒仅在10(7.9)TCID50剂量中有较好的接种效果，鼻内接种仅在10(8.9)TCID50剂量中有较好的接种效果。版权所有爱思唯尔科学有限公司
Adenovirus and poxvirus recombinant vectors are more and more used as live experimental vaccines. In order to compare the efficacy of these vectors to elicit serological response and protection against challenge, two recombinants carrying the same gene (pseudorabies virus gD) were used as experimental vaccines in mice, a permissive species to pseudorabies infection. Two routes were tested: intramuscular (i.m.) and intranasal (i.n.) in order to try to stimulate general and mucosal immune responses. Several doses ranging from 10(2.9) to 10(8.9) TCID50, depending on the vaccines were tested. The estimated log10 (PD50) for the i.m. route were 7.1 +/- 0.2 for the adenovirus vector (Ad-gD), and 7.6 +/- 0.2 for the Nyvac vector (vP900). For the i.n. route, log10 (PD50) of Ad-gD was 7.1 +/- 0.2, and was higher than 7.9 for vP900. While the adenovirus vector proved more efficient than the poxviral vector to elicit antibody response, only a slight difference was observed when comparing the survival times of animals after challenge. Adenovirus was found better only for the 10(7.9) TCID50 dose, when inoculated i.m. Intranasal vaccination appeared efficient only with the adenovirus vector for the TCID50 10(8.9) dose. Copyright (C) 1996 Elsevier Science Ltd.